Upgrade to the Samsung Galaxy Watch 8 and Nab a $50 Amazon Gift Card Preorder Bonus
Amazon is currently offering a limited-time preorder bundle that includes the Galaxy Watch 8 (40mm) and a $50 Amazon gift card for $350, that's the same price as just the watch itself at Samsung -- which means the $50 gift card is essentially thrown in for free. The watch officially releases on July 25, and this deal is valid through July 24. If you've been planning to upgrade, now's the time to lock it in.
Samsung Galaxy Watch 8 bundle: $350 (Bonus $50 gift card included)
See at Amazon
The Samsung Galaxy Watch 8 goes beyond the basics and recently earned a CNET review score of 8.2/10. It impressed our editors with a handful of standout features, including the Antioxidant Index, which checks the carotene levels (a type of antioxidant) in your skin with just a press of your thumb on the sensor, and Vascular Load, which measures strain on your heart while you're asleep.
Hey, did you know? CNET Deals texts are free, easy and save you money.
You'll also get a built-in Running Coach that can analyze your performance and give real-time feedback to help you train better. And if you're someone who takes sleep seriously, you will appreciate upgraded sleep coaching and bedtime guidance. These features recommend an ideal bedtime window after monitoring your circadian rhythm and sleep pressure for three days.
Even better, the watch offers a new, slimmer and more lightweight cushion design that still keeps that classic minimalist look. There's a lot to like about this upgrade, but just make sure you grab the preorder bundle in time to get the best value.
Why this deal matters
Smartwatches, especially those with such advanced features, don't come cheap. This deal gives you both the latest smartwatch and an additional $50 Amazon gift card, which you can use for anything else.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 minutes ago
- Yahoo
Is Now a Good Time To Invest in Uber? Here's What Experts Say
Uber Technologies has been one of the best stocks on Wall Street so far in 2025, with shares rising by about 50% year-to-date to far outpace the broader markets. I'm a Financial Advisor: Read Next: The rideshare company's stock hit a record high of $97.71 in early July. Some analysts see the price reaching $120 by year's end — meaning it could be a good time to invest in Uber. Much of the optimism is based on Uber's strong financial results, which include double-digit revenue growth and a continued uptick in bookings. 'A Real Business' One expert with a positive take on Uber is Edward Corona, a Florida-based trader and publisher of The Options Oracle Newsletter. He's targeting a $107 stock price for the rest of the year as long as the company's current positive trends hold. 'Uber is finally acting like a real business — free cash flow is solid, margins are improving, and they've become the default app for way more than just rides,' Corona told GOBankingRates. Although Uber faces a competitive risk from Tesla's robotaxi, Corona calls that a '2026 problem.' For now, Uber's stock chart has 'been in a steady uptrend, and I like it long here,' he added. How To Turn $100K Into a Million: Is Now A Good Time To Buy? Most experts are upbeat about Uber and recommend buying the stock. The vast majority of analysts polled by MarketWatch — 41 out of 57 — have a 'Buy' rating on the stock. The others rate it either 'Overweight' (4 analysts) or 'Hold' (12). As of July 23, the consensus rating is 'Buy' and the average target price is $101.10. A recent analysis from Motley Fool recommended buying Uber shares 'like there's no tomorrow' and cited the following company strengths: Strong revenue growth driven by double-digit increases in gross bookings for mobility and delivery. Competitive advantages from Uber's 'network effect' and ability to leverage 'vast amounts of data.' Although Uber already operates in more than 15,000 cities worldwide, it's still 'not even close' to reaching its full potential. The stock price is still relatively affordable at less than $100 a share. Among the analysts with a particularly bullish take on Uber is Ken Gawrelski of Wells Fargo. As AInvest noted, Gawrelsk recently maintained his 'Overweight' rating on the stock, and raised his price target to $120 from $100. More From GOBankingRates Are You Rich or Middle Class? 8 Ways To Tell That Go Beyond Your Paycheck This article originally appeared on Is Now a Good Time To Invest in Uber? Here's What Experts Say Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
